Zepbound for sleep apnea: who it's for, results and side effects

What’s going on

Zepbound (tirzepatide) is a once-weekly injection. In December 2024, the FDA approved Zepbound Strong to treat moderate to severe obstructive sleep apnea in adults with obesity. It was the first medicine approved for sleep apnea.

It’s meant to be used with a reduced-calorie diet and more physical activity. It’s prescription only, so a physician decides whether it suits you.

This page is for adults who have been diagnosed, or are being tested. If you haven’t had a sleep test, start with a physician. Only a physician can diagnose sleep apnea.

Who it’s for

The FDA label covers adults with obesity and moderate to severe obstructive sleep apnea. The AASM’s fact sheet for sleep physicians spells that out as:

• A body mass index (BMI) of 30 or more
• An apnea-hypopnea index (AHI) of 15 or more events per hour on a sleep test

Mild sleep apnea, or apnea without obesity, isn’t part of this approval. Your physician may still discuss weight management with you in other ways. Weight loss Strong itself has strong evidence for people with overweight or obesity.

What the trials found

The approval rested on two year-long trials, together called SURMOUNT-OSA. The FDA says they included 469 adults without type 2 diabetes. One trial enrolled people who weren’t using CPAP (or other positive airway pressure); the other enrolled people who were.

People took Zepbound (10 or 15 mg a week) or a placebo for 52 weeks. At the start, the average AHI was about 50 events per hour, which is severe. Average BMI was about 39.

After a year, per the NEJM report:

• Not using CPAP: AHI fell by about 25 events per hour on Zepbound, compared with about 5 on placebo.
• Using CPAP: AHI fell by about 29 events per hour on Zepbound, compared with about 5.5 on placebo.

The AASM fact sheet adds that AHI dropped by about half on average. Between 6 and 7 in 10 people on Zepbound cut their AHI by at least half, compared with about 2 in 10 on placebo. Weight fell by about 18% to 20%, compared with about 2% on placebo.

The FDA says the improvement is likely related to weight loss. The trials were funded by Eli Lilly, which makes Zepbound.

What it doesn’t tell you

• It isn’t a CPAP replacement. The AASM fact sheet says to use it alongside CPAP, an oral appliance or surgery as needed, not instead of CPAP. Many people will still need another treatment.
• There’s no head-to-head evidence. No trial has compared it directly with CPAP, an oral appliance or Inspire.
• Stopping may undo it. The AASM notes people are likely to regain weight if they stop the medicine.

Side effects

The label lists the most common side effects as:

• Nausea, diarrhea, vomiting and constipation
• Stomach pain, indigestion, burping and reflux
• Injection site reactions
• Tiredness, allergic reactions and hair loss

The label says side effects in the sleep apnea trials were similar to those in the weight-loss trials. Most were stomach-related and mild to moderate, per the NEJM report. The dose starts at 2.5 mg and rises slowly over months to lower the risk of stomach problems.

Serious warnings

The label carries a boxed warning: tirzepatide caused thyroid C-cell tumors in rats. It isn’t known whether it does in people. The label also warns about:

• Severe stomach and bowel side effects
• Pancreatitis and gallbladder problems
• Kidney injury from dehydration, which can follow vomiting or diarrhea
• Low blood sugar, especially with insulin or certain diabetes pills
• Serious allergic reactions
• Depression or suicidal thoughts
• Breathing in stomach contents during anesthesia or deep sedation. Tell every doctor and dentist who sedates you that you take it.

Who shouldn’t use it

The label says not to use Zepbound if you have:

• A personal or family history of medullary thyroid cancer
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• A past serious allergic reaction to tirzepatide or its ingredients

It isn’t recommended with severe gastroparesis (slow stomach emptying). Stop it if you become pregnant, and talk with your physician first if you plan to be.

If you take birth control pills, the label advises switching to a non-oral method, or adding a barrier method. Do this for 4 weeks after you start and after each dose increase.

Insurance and Medicare

CMS treats Zepbound for moderate to severe sleep apnea in adults with obesity as a use Medicare Part D plans can cover. The diagnosis matters, because obesity alone is handled differently (see the Bridge below).

Each Part D plan sets its own formulary, cost-sharing and prior approval rules. Ask your plan what it needs, which may include your sleep test results and BMI.

CMS also runs a temporary Medicare GLP-1 Bridge for obesity, from July 2026 through December 2027. People with moderate to severe sleep apnea aren’t eligible for the Bridge; their coverage goes through Part D.

Private plans vary. Ask whether the plan covers Zepbound for sleep apnea, and what paperwork it needs.

What a dentist or doctor can do

Your physician, often a sleep physician or the doctor who manages your weight, decides whether Zepbound fits. They’ll check your health history, other medicines and your sleep test. The AASM fact sheet suggests a repeat sleep test once your weight has settled, to see whether you still need CPAP or another treatment.

Keep using your current treatment in the meantime. A dentist trained in dental sleep medicine can make a custom oral appliance Some on a physician’s prescription.

What not to do

• Don’t stop CPAP or your appliance when you start Zepbound. Change treatment only with your physician, after retesting.
• Don’t start or change doses on your own. The slow dose steps are there to limit side effects.
• Don’t skip the retest. Feeling better or snoring less doesn’t show that your apnea is gone.